A single centre, open label study to evaluate the efficacy of Electrical Muscle Stimulation belt (AbTronic X2/X3) on static and dynamic abdominal endurance in healthy males and females - Nil

Spectrum Clinical Research Pvt Ltd0 个研究点目标入组 90 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 4 期
状态: 已完成
发起方
入组人数: 90

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Pms

入排标准

入选标准

•1.Subjects between the ages of 25 -50 years old,
•2.To have a Body Mass Index (BMI) between 24 - 31,
•3.Not involved in any type of formal abdominal training program within the previous 6 months.
•4.No plans to engage in formal training or new sports that would be expected to affect body weight or abdominal muscles.
•5.Pinch test to measure the thickness of subcutaneous fat.
•6.Waist Circumference measurements.
•7. Subjects willing to continue their routine diet and not to undertake a diet plan for the entire duration of the study.
•8.Subjects with muscle power grade 3 to 5.Defined as Medical Research Council. London: HMSO, 1975 (Annexure II).

排除标准

•1.Subjects with a cardiac pacemaker.
•2.Any abdominal implants.
•3.Subjects who are unable to reach the second tape in supine position during the sit-ups exercise.
•4.No history of recent injury to the low back,
•5.No spine surgery or instrumentations done,
•6.Gravid uterus
•7.Non compliance with the diet instruction (Diet Control for calorie and fluid intake).
•8.Menstrual cycle complications like frequent change in abdominal shape, fluid retention and general well being.
•9.Pregnant and lactating for the past 12 months.
•10.Treatment for any type of cancer within the last six months.
•11.Individuals who have any implanted medical devices (pacemaker, pump, catheter, etc.).
•12.Current or history of a medical condition that would contraindicate treatment with the product, such as epilepsy, hernia, abdominal ulcer, diabetes, or other conditions which, in the opinion of the Investigator, would place the participant at risk.
•13.A current skin disease of any type at the test site (e.g. acne, eczema, psoriasis, burns, abrasions, etc.)
•14.Heavy alcohol consumption in the opinion of the investigator.
•15.A fever in the last 12 hours prior to the first application of the test device.
•16.History of heart disease.
•17.History of stroke.
•18.History of malignant disease.
•19.Insulin dependent diabetes.
•20.Concurrent medication likely to affect the response to the test article or confuse the results of the study (e.g. routine high dose use of any drugs that may artificially affect skin tone).
•21.Individuals who are currently participating in any other clinical. Investigation, or who have participated in a study with the same indication within 1 year.
•22.Participants with skin conditions such as obvious sun damage, increased pigmentation and / or telangectasia.

研究者

发起方

Spectrum Clinical Research Pvt Ltd

相似试验

已完成

3 期

A single center, open label study to evaluate the antimicrobial efficacy of Octenidine Dihydrochloride 0.3% Hand & Body Wash Gel as per CEN 1499 Standard on healthy volunteers

CTRI/2015/05/005816Dishman Pharmaceuticals Chemicals Ltd14

进行中（未招募）

不适用

A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira® vaccine in Healthy ‘Adults’ aged = 18 to < 60 years and in Healthy ‘Older Adults’ aged = 60 years for the 2008/2009 Northern Hemisphere Influenza Seaso

EUCTR2008-005324-93-GBCSL Limited

进行中（未招募）

不适用

EUCTR2008-001422-14-GBCSL Limited

进行中（未招募）

不适用

A Single Centre, Open-Label Study to Evaluate the Immunogenicity and Safety of Enzira Vaccine in Healthy Adults aged = 18 to < 60 years and in Healthy Older Adults aged = 60 years for the 2007/2008 Northern Hemisphere Influenza Season.

EUCTR2007-001465-14-GBCSL Limited

进行中（未招募）

1 期

Evaluation of Tau depositions by brain imaging in subjects with mild cognitive impairment and mild to moderate Alzheimer’s disease in comparison with healthy controls

EUCTR2018-003891-11-GBife Molecular Imaging SA120